Market Overview

UPDATE: Citigroup Reiterates Buy Rating, Raises PT on Medivation

Share:
Related MDVN
In Wake Of Medivation Deal, Argus Thinks Pfizer's Existing Business Is Underrated
Here Are All The Big Biotech Mergers In 2016
Biotech Forum Daily Digest: Mylan Adjusts Course, Who Is Next Midcap Buyout Target After Medivation? Spotlight On NeuroDerm (Seeking Alpha)

In a report published Wednesday, Citigroup reiterated its Buy rating on Medivation (NASDAQ: MDVN), and raised its price target from $64.50 to $70.00.

Citigroup noted, “We are raising ests to reflect the higher Xtandi US price, earlier than expected FDA approval for post-chemo, partially offset by a more modest tiered ex-US royalty rate, and a slight delay to timing of pre-chemo ph 3 data. Our model is still conservative as it models a slower and shallower launch relative to Zytiga, conservative ex-US pricing, and does not account for potential rapid approval in Europe by March (based on Zytiga's approval timing). Based on the first 2 wks of prescriptions, Xtandi is off to a solid launch in the U.S. Our doc checks are very constructive and compendia listing for pre-chemo might be received soon. Despite the strong appreciation, we remain bullish on the stock especially because our new analysis suggests that the pre-chemo market should be bigger than expected. We are raising EPS ests. Our new TP is $70 based on a 30x (unchanged) our 2015 EPS est of $3.10.”

Medivation closed on Tuesday at $56.96.

Latest Ratings for MDVN

DateFirmActionFromTo
Aug 2016BMO CapitalMaintainsMarket Perform
Aug 2016CitigroupDowngradesBuyHold
Aug 2016Credit SuisseDowngradesOutperformNeutral

View More Analyst Ratings for MDVN
View the Latest Analyst Ratings

Posted-In: CitigroupAnalyst Color Price Target Analyst Ratings

 

Related Articles (MDVN)

View Comments and Join the Discussion!